ImageneBio, Inc. (IMA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ImageneBio, Inc. (IMA) has a cash flow conversion efficiency ratio of -0.120x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.80 Million) by net assets ($123.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ImageneBio, Inc. balance sheet quality to measure how much of total assets are equity-financed.
ImageneBio, Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how ImageneBio, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check IMA cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
ImageneBio, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ImageneBio, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aplisens SA
WAR:APN
|
0.047x |
|
Lowell Resources Fund
AU:LRT
|
0.028x |
|
Novotek AB
ST:NTEK-B
|
0.124x |
|
Health In Tech, Inc. Class A Common Stock
NASDAQ:HIT
|
-0.154x |
|
Austco Healthcare Ltd
AU:AHC
|
0.216x |
|
Ebusco Holding BV
AS:EBUS
|
-0.448x |
|
Gozco Plantations Tbk
JK:GZCO
|
-0.089x |
|
Stillwater Critical Minerals Corp
V:PGE
|
-0.123x |
Annual Cash Flow Conversion Efficiency for ImageneBio, Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of ImageneBio, Inc. from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see market value of ImageneBio, Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $133.14 Million | $-47.84 Million | -0.359x | +1.63% |
| 2024-12-31 | $125.93 Million | $-46.00 Million | -0.365x | +22.23% |
| 2023-12-31 | $169.76 Million | $-79.74 Million | -0.470x | +6.84% |
| 2022-12-31 | $146.97 Million | $-74.11 Million | -0.504x | -73.97% |
| 2021-12-31 | $207.88 Million | $-60.25 Million | -0.290x | -177.43% |
| 2020-12-31 | $-101.05 Million | $-37.83 Million | 0.374x | +148.01% |
| 2019-12-31 | $-61.46 Million | $47.93 Million | -0.780x | -407.93% |
| 2018-12-31 | $-45.84 Million | $-11.61 Million | 0.253x | -- |
About ImageneBio, Inc.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerl… Read more